KEYNOTE-024 investigated non-small cell lung cancer patients who had PD-L1 expression of more than 50% and found that single-agent pembrolizumab induced higher response rates, PFS, and OS than chemotherapy alone (23). The gene discussed is CD274; the disease is non-small cell lung carcinoma.